Interleukin-12 enhances peripheral hematopoiesis in vivo

J. D. Jackson, Y. Yan, M. J. Brunda, L. S. Kelsey, James E Talmadge

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Interleukin 12 (IL-12) is a cytokine that supports the proliferation and activation of cytotoxic T lymphocytes and natural killer (NK) cells. Recent evidence has suggested that IL-12 also has hematopoietic activities in vitro. We report studies that show that IL-12 has significant in vivo hematopoietic stimulating activity that includes enhancement of peripheral (splenic) hematopoiesis and mobilization of hematopoietic progenitor cells to the peripheral circulation. A single injection of recombinant murine IL-12 significantly reduced the number of bone marrow (BM) colony-forming unit granulocyte-macrophage (CFU-GM) in a time-dependent manner, while concomitantly stimulating high proliferative potential. In contrast, splenic CFU-GM and HPP were increased in a time- and dose-dependent manner. Chronic administration of IL-12 resulted in significant splenic hyperplasia with increased progenitor cells, increased circulating progenitor cells, and BM hypoplasia with decreased progenitor cells. These data show that IL-12 has significant in vivo hematopoietic effects that include the ability to mobilize progenitor cells to the peripheral circulation, which may prove to be of significant benefit for peripheral blood stem cell transplantation. Thus, IL-12 has potential to be an important agent for clinical transplantation because of its hematopoietic mobilization and its previously shown immune augmenting and therapeutic activities. This combination of hematopoietic and immune functions is unique and not achievable with currently used hematopoietic growth factors.

Original languageEnglish (US)
Pages (from-to)2371-2376
Number of pages6
JournalBlood
Volume85
Issue number9
StatePublished - Jan 1 1995

Fingerprint

Hematopoiesis
Interleukin-12
Stem Cells
Granulocyte-Macrophage Progenitor Cells
Macrophages
Bone
Bone Marrow
Peripheral Blood Stem Cell Transplantation
T-cells
Cytotoxic T-Lymphocytes
Hematopoietic Stem Cells
Stem cells
Natural Killer Cells
Hyperplasia
Intercellular Signaling Peptides and Proteins
Blood
Transplantation
Chemical activation
Cytokines
Injections

ASJC Scopus subject areas

  • Hematology

Cite this

Jackson, J. D., Yan, Y., Brunda, M. J., Kelsey, L. S., & Talmadge, J. E. (1995). Interleukin-12 enhances peripheral hematopoiesis in vivo. Blood, 85(9), 2371-2376.

Interleukin-12 enhances peripheral hematopoiesis in vivo. / Jackson, J. D.; Yan, Y.; Brunda, M. J.; Kelsey, L. S.; Talmadge, James E.

In: Blood, Vol. 85, No. 9, 01.01.1995, p. 2371-2376.

Research output: Contribution to journalArticle

Jackson, JD, Yan, Y, Brunda, MJ, Kelsey, LS & Talmadge, JE 1995, 'Interleukin-12 enhances peripheral hematopoiesis in vivo', Blood, vol. 85, no. 9, pp. 2371-2376.
Jackson JD, Yan Y, Brunda MJ, Kelsey LS, Talmadge JE. Interleukin-12 enhances peripheral hematopoiesis in vivo. Blood. 1995 Jan 1;85(9):2371-2376.
Jackson, J. D. ; Yan, Y. ; Brunda, M. J. ; Kelsey, L. S. ; Talmadge, James E. / Interleukin-12 enhances peripheral hematopoiesis in vivo. In: Blood. 1995 ; Vol. 85, No. 9. pp. 2371-2376.
@article{13c8a14a179f448db70a7725310439ec,
title = "Interleukin-12 enhances peripheral hematopoiesis in vivo",
abstract = "Interleukin 12 (IL-12) is a cytokine that supports the proliferation and activation of cytotoxic T lymphocytes and natural killer (NK) cells. Recent evidence has suggested that IL-12 also has hematopoietic activities in vitro. We report studies that show that IL-12 has significant in vivo hematopoietic stimulating activity that includes enhancement of peripheral (splenic) hematopoiesis and mobilization of hematopoietic progenitor cells to the peripheral circulation. A single injection of recombinant murine IL-12 significantly reduced the number of bone marrow (BM) colony-forming unit granulocyte-macrophage (CFU-GM) in a time-dependent manner, while concomitantly stimulating high proliferative potential. In contrast, splenic CFU-GM and HPP were increased in a time- and dose-dependent manner. Chronic administration of IL-12 resulted in significant splenic hyperplasia with increased progenitor cells, increased circulating progenitor cells, and BM hypoplasia with decreased progenitor cells. These data show that IL-12 has significant in vivo hematopoietic effects that include the ability to mobilize progenitor cells to the peripheral circulation, which may prove to be of significant benefit for peripheral blood stem cell transplantation. Thus, IL-12 has potential to be an important agent for clinical transplantation because of its hematopoietic mobilization and its previously shown immune augmenting and therapeutic activities. This combination of hematopoietic and immune functions is unique and not achievable with currently used hematopoietic growth factors.",
author = "Jackson, {J. D.} and Y. Yan and Brunda, {M. J.} and Kelsey, {L. S.} and Talmadge, {James E}",
year = "1995",
month = "1",
day = "1",
language = "English (US)",
volume = "85",
pages = "2371--2376",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "9",

}

TY - JOUR

T1 - Interleukin-12 enhances peripheral hematopoiesis in vivo

AU - Jackson, J. D.

AU - Yan, Y.

AU - Brunda, M. J.

AU - Kelsey, L. S.

AU - Talmadge, James E

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Interleukin 12 (IL-12) is a cytokine that supports the proliferation and activation of cytotoxic T lymphocytes and natural killer (NK) cells. Recent evidence has suggested that IL-12 also has hematopoietic activities in vitro. We report studies that show that IL-12 has significant in vivo hematopoietic stimulating activity that includes enhancement of peripheral (splenic) hematopoiesis and mobilization of hematopoietic progenitor cells to the peripheral circulation. A single injection of recombinant murine IL-12 significantly reduced the number of bone marrow (BM) colony-forming unit granulocyte-macrophage (CFU-GM) in a time-dependent manner, while concomitantly stimulating high proliferative potential. In contrast, splenic CFU-GM and HPP were increased in a time- and dose-dependent manner. Chronic administration of IL-12 resulted in significant splenic hyperplasia with increased progenitor cells, increased circulating progenitor cells, and BM hypoplasia with decreased progenitor cells. These data show that IL-12 has significant in vivo hematopoietic effects that include the ability to mobilize progenitor cells to the peripheral circulation, which may prove to be of significant benefit for peripheral blood stem cell transplantation. Thus, IL-12 has potential to be an important agent for clinical transplantation because of its hematopoietic mobilization and its previously shown immune augmenting and therapeutic activities. This combination of hematopoietic and immune functions is unique and not achievable with currently used hematopoietic growth factors.

AB - Interleukin 12 (IL-12) is a cytokine that supports the proliferation and activation of cytotoxic T lymphocytes and natural killer (NK) cells. Recent evidence has suggested that IL-12 also has hematopoietic activities in vitro. We report studies that show that IL-12 has significant in vivo hematopoietic stimulating activity that includes enhancement of peripheral (splenic) hematopoiesis and mobilization of hematopoietic progenitor cells to the peripheral circulation. A single injection of recombinant murine IL-12 significantly reduced the number of bone marrow (BM) colony-forming unit granulocyte-macrophage (CFU-GM) in a time-dependent manner, while concomitantly stimulating high proliferative potential. In contrast, splenic CFU-GM and HPP were increased in a time- and dose-dependent manner. Chronic administration of IL-12 resulted in significant splenic hyperplasia with increased progenitor cells, increased circulating progenitor cells, and BM hypoplasia with decreased progenitor cells. These data show that IL-12 has significant in vivo hematopoietic effects that include the ability to mobilize progenitor cells to the peripheral circulation, which may prove to be of significant benefit for peripheral blood stem cell transplantation. Thus, IL-12 has potential to be an important agent for clinical transplantation because of its hematopoietic mobilization and its previously shown immune augmenting and therapeutic activities. This combination of hematopoietic and immune functions is unique and not achievable with currently used hematopoietic growth factors.

UR - http://www.scopus.com/inward/record.url?scp=0028932525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028932525&partnerID=8YFLogxK

M3 - Article

VL - 85

SP - 2371

EP - 2376

JO - Blood

JF - Blood

SN - 0006-4971

IS - 9

ER -